RFS Pharma presents novel DAPN phosphoramidate prodrugs with promising activity against HCV Jan. 2, 2014
Phase II results presented for the new oral combination of faldaprevir, deleobuvir and PPI-668 Dec. 31, 2013
NAMPT as a new genetic marker associated with susceptibility, severity and outcome of CAD Dec. 31, 2013
RSS